Using an ursodeoxycholic acid with mebeverine in patients with cholelithiasis after cholecystectomy

DOI: https://doi.org/10.29296/25877305-2021-09-05
Download full text PDF
Issue: 
9
Year: 
2021

Professor Yu. Uspenskiy(1, 2), MD; Professor Yu. Fominykh(1, 2), MD; K. Nadzhafova(1); A.
Kosheev(3), Candidate of Medical Sciences; A. Kosareva(1); D. Nikitina(1) (1)St.Petersburg State Pediatric
Medical University (2)Pavlov First St.Petersburg State Medical University (3)Mechnikov North-Western State
Medical University

Insufficient attention is often paid to the management of patients with cholelithiasis who have undergone cholecystectomy. The quality of life of such patients may remain low after the intervention due to a number of organic and functional disorders. The aim of our work was to evaluate the effectiveness and safety of taking a universal hepatoprotector based on ursodeoxycholic acid (UDCA) Exhol 500 mg and a selective antispasmodic based on mebeverin Sparex 200 mg in patients with cholelithiasis who underwent cholecystectomy. Materials and methods. The study involved 40 patients who passed elective cholecystectomy. The patients were divided into 2 groups of 20 people, the first group received treatment with a combination of drugs after surgical treatment, the second group received only non-drug recommendations. All patients before the operation and 3 months after it underwent a biochemical blood test, ultrasound of the abdominal cavity, MRCPG, gastroenterological complaints, quality of life and psychological status were evaluated. Conclusion. The complex scheme, including the appointment of a hepatoprotector based on UDCA (Exhol) and a selective antispasmodic (Sparex), demonstrates high efficacy and safety, and can be recommended for the management of patients with cholelithiasis who have undergone cholecystecomy.
Keywords: 
gastroenterology
cholelithiasis
cholecystectomy
ursodeoxycholic acid
mebeverine

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Uspenskij Ju.P., Fominyh Ju.A., Nadzhafova K.N. i dr. Patogeneticheskie aspekty razvitija zhelchnokamennoj bolezni u bol'nyh s metabolicheskim sindromom. Ter arh. 2021; 93 (2): 209–14 [For citation: Uspenskiy Yu.P., Fominykh Yu.A., Nadzhafova K.N. et al. Pathogenetic aspects of the development of cholelithiasis in patients with metabolic syndrome. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (2): 209–14 (in Russ.)]. DOI: 10.26442/00403660.2021.02.200616
  2. Swarne E., Srikanth M.S., Shreyas A. al. Recent advances, novel targets doktor meditsinskih nauk, professor,and treatments for cholelithiasis; a narrative review. Review. Eur J Pharmacol. 2021; 5 (908): 174376. DOI: 10.1016/j.ejphar.2021.174376
  3. Uspenskij Ju.P., Fominyh Ju.A., Nadzhafova K.N. i dr. Rol' lipidov syvorotki krovi v razvitii zhelchnokamennoj bolezni. Universitetskij terapevticheskij vestnik. 2019; 1 (1): 59–71 [Uspenskiy Yu.P., Fominykh Yu.A., Nadzhafova K.N. et al. The role of serum lipids in the development of gallstone dis ease. University Therapeutic Journal. 2019; 1 (1): 59–71 (in Russ.)].
  4. Latenstein C.S.S., Hannink G., van der Bilt J.D.W. et al. A clinical decision tool for selection of patients with symptomatic cholelithiasis for cholecystectomy based on reduction of pain and a pain-free state following surgery. JAMA Surg. 2021; 11: e213706. DOI: 10.1001/jamasurg.2021.3706
  5. Uspenskij Ju.P., Fominyh Ju.A., Nadzhafova K.N. i dr. Otdalennye posledstvija laparoskopicheskoj holetsistektomii. Universitetskij terapevticheskij vestnik. 2020; 2 (2): 23–9 [Uspenskiy Yu.P., Fominykh Yu.A., Nadzhafova K.N. et al. Long-term effects of laparoscopic cholecystectomy. University Therapeutic Journal. 2020; 2 (2): 23–9 (in Russ.)].
  6. Mitusheva E.I., Sajfutdinov R.G., Shajmardanov R.Sh. Gepatopankreatobiliarnaja sistema i kachestvo zhizni posle holetsistektomii. Eksperimental'naja i klinicheskaja gastroenterologija. 2021; 3: 158–66 [Mitusheva E.I., Sayfutdinov R.G., Shaimardanov R.S. State of Hepatopancreatobiliary system and post-cholecystectomy quality of life. Experimental and Clinical Gastroenterology. 2021; 3: 158–66 (in Russ.)]. DOI: 10.31146/1682-8658-ecg-187-3-158-166
  7. Agafonova N.A. Postholetsistektomicheskij sindrom: voprosy diagnostiki i lechenija. M.: Prima: Print, 2015; 156 s. [Agafonova N.A. Postcholecystectomy syndrome: issues of diagnosis and treatment. M.: Prima: Print, 2015; 156 s. (in Russ.)].
  8. Veligotskij N.N., Lazutkina E.A., Arutjunov S.E. i dr. Postholetsistektomicheskij sindrom s pozitsii hirurga i gastroenterologa. Ukrainskij zhurnal hirurgii. 2018; 2 (37): 16–21 [Veligotsky N.N., Lazutkina E.A., Arutyunov S.E. et al. Postcholecystectomy syndrome from the position of surgeon and gastroenterologist. Ukrainian Journal of Surgery. 2018; 2 (37): 16–21 (in Russ.)]. DOI: 10.22141/1997-2938.2.37.2018.147842
  9. Clout M., Blazeby J., Rogers C. Randomised controlled trial to establish the clinical and cost-effectiveness of expectant management versus preoperative imaging with magnetic resonance cholangiopancreatography in patients with symptomatic gallbladder disease undergoing laparoscopic cholecystectomy at low or moderate risk of common bile duct stones (The Sunflower Study): a study protocol. BMJ Open. 2021; 11 (6): e044281. DOI: 10.1136/bmjopen-2020-044281
  10. Minushkin O.N. Sovremennye predstavlenija o postholetsistektomnom sindrome v svete rekomendatsij Rimskogo konsensusa II–III. Meditsinskij sovet. 2015; 13: 70–5 [Minushkin O.N. Current views on postcholecystectomy syndrome according to the Rome Consensus II–III guidelines. Meditsinskiy sovet = Medical Council. 2015; 13: 70–5 (in Russ.)]. DOI: 10.21518/2079-701X-2015-13-70-75
  11. Mahov V.M., Volodina T.V., Panferov A.S. i dr. Polinozologicheskij effekt ursodezoksiholevoj kisloty. Opyt primenenija. Meditsinskij sovet. 2016; 14: 62–7 [Makhov V.M., Volodina T.V., Panferov A.S., Turko T.V. Polynosological effects of ursodeoxycholic acid (UDCA). Practice of using. Meditsinskiy sovet = Medical Council. 2016; 14: 62–7 (in Russ.)]. DOI: 10.21518/2079-701X-2016-14-62-67
  12. Uspenskij Ju.P., Baryshnikova N.V, Fominyh Ju.A. i dr. Effektivnost' i bezopasnost' primenenija kombinirovannoj shemy s preparatami ursodezoksiholevoj kisloty i mebeverina u patsientov s metabolicheskim sindromom. Lechaschij vrach. 2018; 8: 33–7 [Uspenskiy Yu.P., Baryshnikova N.V, Fominykh Yu.A. et al. Efficacy and safety of the use of the combined scheme with ursodeoxycholic acid drugs and mebeverine in patients with metabolic syndrome. Lechashchii vrach. 2018; 8: 33–7 (in Russ.)].
  13. Radchenko V.G., Seliverstov P.V., Sitkin S.I. Novye aspekty farmakologicheskogo dejstvija ursodezoksiholevoj kisloty. Eksperimental'naja i klinicheskaja gastroenterologija. 2014; 8 (108): 4–10 [Radchenko V.G., Seliverstov P.V., Sitkin S.I. New aspects of pharmacological effects of ursodeoxycholic acid. Experimental and Clinical Gastroenterology. 2014; 8 (108): 4–10 (in Russ.)].
  14. Bakulin I.G., Avalueva E.B., Serkova M.Ju. i dr. Biliarnyj sladzh: patogenez, etiologija i lekarstvennaja terapija. Ter arh. 2021; 93 (2): 179–86 [Bakulin I.G., Avalueva E.B., Serkova M.U. et al. Biliary sludge: pathogenesis, etiology and drug therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2021; 93 (2): 179–86 (in Russ.)]. DOI: 10.26442/00403660.2021.02.200638
  15. Ruban A.P., Bagmet A.D. Zhelchnokamennaja bolezn', holetsistektomija – chto dal'she? Kurortnaja meditsina. 2014; 3: 97–103 [Ruban A.P., Bagmet A.D. Cholelithiasis, cholecystectomy – what’s next? Kurortnaya medicina. 2014; 3: 97–103 (in Russ.)].
  16. Oprosnik GSRS (russkojazychnaja versija) [elektronnyj resurs]. [The GSRS questionnaire (Russian version) [electronic resource] (in Russ.)]. URL: https://medlec.org/lek-194496.html (data obraschenija/accessed: 16.08.2021).